National Institutes of Health Awards Grant to SINTX Technologies for Development of 3D Printed Craniomaxillofacial Devices
10 mars 2022 09h00 HE | SINTX Technologies, Inc.
SALT LAKE CITY, March 10, 2022 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. ( (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer of advanced ceramics,...
Rendever Logo.png
Rendever Receives $2M NIH Phase II Grant to Further Research the Impact of Virtual Reality on the Aging Population
17 août 2021 11h23 HE | Rendever
BOSTON, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Rendever, a virtual reality (VR) platform built to help seniors overcome social isolation through shared experiences, today announces that it has been...
Trevena Reports Second Quarter 2021 Results
12 août 2021 07h00 HE | Trevena Inc.
Company reaffirms YE goal of 100 formulary wins OLINVYK respiratory physiology study currently enrolling, topline data expected by YE 2021 NIH / Vanderbilt University Medical Center-led...
Trevena Announces First Patient Enrolled in NIH-Funded ACTIV-4 Host Tissue Trial of TRV027 for COVID-19
26 juil. 2021 07h00 HE | Trevena Inc.
CHESTERBROOK, Pa., July 26, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces NIH Has Resumed Recruiting Patients in Proof-of-Concept Study for TRV734 in Opioid Use Disorder
16 juin 2021 07h00 HE | Trevena Inc.
-- TRV734 reduced drug-seeking behavior in a preclinical model of relapse, suggesting its utility as a novel oral maintenance treatment for opioid use disorder The study is being conducted and...
February is American Heart Month - Top Tips to Keep Your Ticker in Tip Top Shape By Dr Aimee Harris-Newon
13 févr. 2021 13h19 HE | Dr. Aimee Harris-Newon
Bloomingdale, Illinois, Feb. 13, 2021 (GLOBE NEWSWIRE) -- Every February Americans observe American Heart Month to raise awareness and reaffirm the importance of a healthy heart. Heart disease...
Provectus Biopharmaceuticals Announces Presentation of Preliminary Data from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Refractory Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020
17 sept. 2020 07h00 HE | Provectus Biopharmaceuticals Inc.
36% ORR and 64% DCR (RECIST 1.1)PV-10-induced, tumor-specific restoration of T cell functionData compare favorably to approved and investigational therapies for patient population KNOXVILLE, TN,...
Provectus Biopharmaceuticals Announces Presentation of 2-Year Landmark Data from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Naïve Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020
17 sept. 2020 06h00 HE | Provectus Biopharmaceuticals Inc.
62% 2-year OS; median OS not reachedStable, non-overlapping safety profileClinical synergy between PV-10 and immune checkpoint blockadeData compare favorably to approved therapies for patient...
10 sept. 2020 08h00 HE | PetVivo Holdings, Inc.
MINNEAPOLIS, Sept. 10, 2020 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for...
Rafael Pharmaceuticals Enters into Collaboration with the National Institutes of Health (NIH) to Test CPI-613® (devimistat) in Cytokine Independent (Acute) HTLV-1 Associated Adult T-cell Leukemia/Lymphoma
17 oct. 2019 09h00 HE | Rafael Pharmaceutical Inc.
Cranbury, NJ, Oct. 17, 2019 (GLOBE NEWSWIRE) --  Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that...